⚠ Disclaimer: This report is generated using AI tools and is for informational purposes only. It does not constitute investment advice. Please consult a registered financial advisor before making any investment decisions.

METROPOLIS - Fundamental Analysis: Financial Health & Valuation

Back to List

Rating: 3.5

Last Updated Time : 25 May 26, 01:36 am

Fundamental Rating: 3.5

Stock Code METROPOLIS Market Cap 10,783 Cr. Current Price 520 ₹ High / Low 600 ₹
Stock P/E 66.2 Book Value 64.0 ₹ Dividend Yield 0.39 % ROCE 16.8 %
ROE 13.1 % Face Value 2.00 ₹ DMA 50 492 ₹ DMA 200 481 ₹
Chg in FII Hold -1.25 % Chg in DII Hold 1.07 % PAT Qtr 43.3 Cr. PAT Prev Qtr 38.0 Cr.
RSI 55.5 MACD 13.6 Volume 1,49,686 Avg Vol 1Wk 2,80,055
Low price 400 ₹ High price 600 ₹ PEG Ratio 12.1 Debt to equity 0.11
52w Index 59.7 % Qtr Profit Var 82.6 % EPS 7.60 ₹ Industry PE 43.3

📊 Core Financials: Metropolis Healthcare reported quarterly PAT of ₹43.3 Cr (up from ₹38.0 Cr), showing healthy growth. ROE at 13.1% and ROCE at 16.8% reflect moderate efficiency. Debt-to-equity ratio of 0.11 indicates low leverage. EPS at ₹7.60 is modest relative to market cap, highlighting limited earnings power despite profitability growth.

💹 Valuation Indicators: Stock P/E of 66.2 is significantly higher than the industry average (43.3), suggesting overvaluation. Book value at ₹64 vs CMP ₹520 shows a steep premium. PEG ratio of 12.1 indicates earnings growth is not keeping pace with valuation. Intrinsic value appears lower than CMP, limiting near-term upside potential.

🏥 Business Model & Advantage: Metropolis operates in diagnostic services, with competitive advantage in brand recognition, wide network of labs, and strong presence in urban markets. However, valuations remain stretched, and efficiency metrics are moderate compared to peers.

📈 Entry Zone & Holding Guidance: The stock trades above DMA 50 (₹492) and DMA 200 (₹481), showing momentum. RSI at 55.5 indicates neutral conditions. A better entry zone would be closer to ₹480–₹500. Long-term holding is viable given healthcare demand, but investors should be cautious of high valuations.

Positive

  • ✅ Low debt-to-equity ratio (0.11), minimal leverage risk

  • ✅ Quarterly PAT growth (₹38 Cr → ₹43.3 Cr)

  • ✅ DII holding increased by 1.07%, showing domestic institutional confidence

Limitation

  • ⚠️ Very high P/E (66.2) vs industry average (43.3)

  • ⚠️ PEG ratio of 12.1, showing slower earnings growth relative to valuation

  • ⚠️ EPS at ₹7.60, reflecting modest earnings power

Company Negative News

  • 📉 FII holding decreased by 1.25%, showing reduced foreign investor confidence

Company Positive News

  • 📈 Quarterly profit growth of 82.6% year-on-year indicates strong operational momentum

  • 📈 Strong brand presence and diagnostic network support long-term growth

Industry

  • 🌐 Diagnostics industry PE at 43.3, reflecting moderate valuations compared to Metropolis’s premium

  • 🌐 Long-term demand supported by rising healthcare awareness and preventive diagnostics

Conclusion

🔎 Metropolis Healthcare is fundamentally stable with low debt and strong brand presence, but suffers from modest efficiency metrics and high valuations. Entry near ₹480–₹500 offers better risk-reward. Long-term investors may hold cautiously, supported by healthcare demand, but valuation risks must be monitored closely.

For deeper insights, you could explore a peer comparison or a valuation analysis to assess its position against competitors and intrinsic value.

Back to List
Technical Analysis
Fundamental Analysis

NIFTY 50 - Fundamental Stock Watchlist

NEXT 50 - Fundamental Stock Watchlist

MIDCAP - Fundamental Stock Watchlist

SMALLCAP - Fundamental Stock Watchlist